ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS NEX I
CODUCT CHARA

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

MiPet Easecto 5 mg chewable tablets for dogs 1.3-2.5 kg

MiPet Easecto 10 mg chewable tablets for dogs > 2.5-5 kg

MiPet Easecto 20 mg chewable tablets for dogs > 5-10 kg

MiPet Easecto 40 mg chewable tablets for dogs > 10–20 kg

MiPet Easecto 80 mg chewable tablets for dogs > 20–40 kg

MiPet Easecto 120 mg chewable tablets for dogs > 40–60 kg

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains:

Active substance:

MiPet Easecto chewable tablets	sarolaner (mg)
for dogs 1.3–2.5 kg	5
for dogs $> 2.5-5$ kg	10
for dogs $> 5-10 \text{ kg}$	20
for dogs > 10–20 kg	40
for dogs > 20–40 kg	80
for dogs > 40–60 kg	120

Excipients:

Qualitative composition of excipients and other constituents		
Hypromellose acetate succinate, medium grade		
Lactose monohydrate		
Sodium starch glycolate		
Silica, colloidal anhydrous		
Magnesium stearate		
Maize starch		
Confectioner's sugar		
Glucose, liquid (81.5% solids)		
Spray dried pork liver powder		
Hydrolysed vegetable protein		
Gelatin type A		
Wheat germ		
Calcium hydrogen phosphate anhydrous		

Mottled brown coloured, square shaped chewable tablets with rounded edges. The number embossed on one side refers to the strength (mg) of the tablets: "5", "10", "20", "40", "80" or "120".

3. CLINICAL INFORMATION

3.1 Target species

Dogs.

3.2 Indications for use for each target species

For the treatment of tick infestations (*Dermacentor reticulatus*, *Ixodes hexagonus*, *Ixodes ricinus* and *Rhipicephalus sanguineus*). The veterinary medicinal product has immediate and persistent tick killing activity for at least 5 weeks.

For the treatment of flea infestations (*Ctenocephalides felis* and *Ctenocephalides canis*). The veterinary medicinal product has immediate and persistent flea killing activity against new infestations for at least 5 weeks. The veterinary medicinal product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD).

For the treatment of sarcoptic mange (Sarcoptes scabiei).

For the treatment of ear mite infestations (Otodectes cynotis).

For the treatment of demodicosis (*Demodex canis*).

For reduction of the risk of infection with *Babesia canis via transmission* by *Dermacentor reticulatus* for 28 days after treatment. The effect is indirect due to the activity of the veterinary medicinal product against the vector.

Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

3.3 Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

3.4 Special warnings

Transmission of *B. canis canis* cannot be completely excluded since *D. reticulatus* ticks have to attach to the host before being killed. As an acaricidal effect against *D. reticulatus* may take up to 48 hours, transmission of *B. canis canis* during the first 48 hours cannot be excluded.

The use of the veterinary medicinal product should be based on the local epidemiological situation including knowledge of the prevalent tick species as transmission of *B. canis* by tick species other than *D. reticulatus* is possible and should be part of an integrated control program to prevent the transmission of *Babesia canis*.

3.5 Special precautions for use

Special precautions for safe use in the target species:

In the absence of available data, treatment of puppies less than 8 weeks of age and/or dogs less than 1.3 kg bodyweight should be based on a benefit-risk assessment by the responsible veterinarian.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Wash hands after handling the veterinary medicinal product.

The accidental ingestion of the veterinary medicinal product may potentially result in adverse effects, such as transient excitatory neurological signs. To prevent children from accessing the veterinary

medicinal product, only one chewable tablet at a time should be removed from the blister pack and only when required. The blister pack should then be returned into the carton immediately after use and the carton should be stored out of the sight and reach of children. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

<u>Special precautions for the protection of the environment:</u> Not applicable.

3.6 Adverse events

Dogs:

Very rare	gastrointestinal signs (such as vomiting,
(<1 animal / 10,000 animals treated, including	diarrhoea) ¹
isolated reports):	systemic disorders (such as lethargy, anorexia) ¹
	neurological signs (such as tremor, ataxia,
	convulsions) ²

¹Mild and transient.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established during pregnancy and lactation or in animals intended for breeding. Laboratory studies in rats and rabbits have not produced any evidence of any teratogenic effects.

Pregnancy and lactation:

The use in these animals is not recommended

Fertility:

The use in breeding animals is not recommended.

3.8 Interaction with other medicinal products and other forms of interaction

None known.

During clinical field trials, no interactions between this veterinary medicinal product and routinely used veterinary medicinal products were observed.

In laboratory safety studies, no interactions were observed when sarolaner was co-administered with milbemycin oxime, moxidectin and pyrantel pamoate. (In these studies efficacy was not investigated).

Sarolaner is highly bound to plasma proteins and might compete with other highly bound drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) and the cumarin derivative warfarin.

3.9 Administration routes and dosage

For oral use.

Tablets can be administered with or without food.

The veterinary medicinal product should be administered at a dose of 2–4 mg/kg bodyweight in accordance with the following table:

²In most cases these signs are transient.

Bodyweight (kg)	Tablet strength (mg sarolaner)	Number of tablets to be administered
1.3–2.5	5	One
> 2.5–5	10	One
> 5–10	20	One
> 10–20	40	One
> 20 -40	80	One
> 40–60	120	One
> 60	Appropriate combinate	nation of tablets

Use appropriate combination of available strengths to achieve the recommended dose of 2–4 mg/kg To ensure a correct dosage, body weight should be determined as accurately as possible.

The tablets of this veterinary medicinal product are chewable and palatable and readily consumed by dogs when offered by the owner. If the tablet is not taken up voluntarily by the dog it can also be given with food or directly into the mouth. The tablets should not be divided.

Treatment schedule:

For optimal control of tick and flea infestations, the veterinary medicinal product should be administered at monthly intervals and continue throughout the flea and/or tick season based on local epidemiological situations.

For the treatment of ear mite infestations (*Otodectes cynotis*) a single dose should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.

For the treatment of sarcoptic mange (caused by *Sarcoptes scabiei* var. *canis*) a single dose should be administered at monthly intervals for two consecutive months.

For the treatment of demodicosis (caused by *Demodex canis*) the administration of a single dose once monthly for three consecutive months is efficacious and leads to a marked improvement of clinical signs. Treatment should be continued until skin scrapings are negative on at least two consecutive occasions one month apart. As demodicosis is a multi-factorial disease, it is advisable to also treat any underlying disease appropriately.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

In a margin of safety study, the veterinary medicinal product was administered orally to 8 week old Beagle puppies at doses of 0, 1, 3, and 5 times the maximum exposure dose of 4 mg/kg at 28 day intervals for 10 doses. No adverse effects were observed at the maximum exposure dose of 4 mg/kg. In the overdose groups, transient and self-limiting neurological signs were observed in some animals: mild tremors at 3 times the maximum exposure dose and convulsions at 5 times the maximum exposure dose. All dogs recovered without treatment.

Sarolaner is well tolerated in Collies with a deficient multidrug-resistance-protein 1 (MDR1 -/-) following single oral administration at 5 times the recommended dose. No treatment-related clinical signs were observed.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Not applicable.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code: QP53BE03

4.2 Pharmacodynamics

Sarolaner is an acaricide and insecticide belonging to the isoxazoline family. The primary target of action of sarolaner in insects and acarines is functional blockade of ligand-gated chloride channels (GABA-receptors and glutamate-receptors). Sarolaner blocks GABA- and glutamate-gated chloride channels in the central nervous system of insects and acarines. Disruption of these receptors by sarolaner prevents the uptake of chloride ions by GABA and glutamate gated ion channels, thus resulting in increased nerve stimulation and death of the target parasite. Sarolaner exhibits higher functional potency to block insect/acarine receptors compared to mammalian receptors. Sarolaner does not interact with known insecticidal binding sites of nicotinic or other GABAergic insecticides such as neonicotinoids, fiproles, milbemycins, avermectins, and cyclodienes. Sarolaner is active against adult fleas (Ctenocephalides felis and Ctenocephalides canis) as well as several tick species such as Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus, Rhipicephalus sanguineus and the mites Demodex canis, Otodectes cynotis and Sarcoptes scabiei.

For fleas, the onset of efficacy is within 8 hours of attachment during the 28 day period after the administration of the veterinary medicinal product. For ticks (*I. ricinus*), the onset of efficacy is within 12 hours of attachment during the 28 day period after the administration of the veterinary medicinal product. Ticks on the animal prior to administration are killed within 24 hours.

The veterinary medicinal product kills newly emerged fleas on the dog before they can lay eggs and therefore it prevents environmental flea contamination in areas to which the dog has access.

4.3 Pharmacokinetics

The bioavailability of sarolaner following oral dosing was high at > 85%. Sarolaner was dose proportional in Beagle dogs when dosed from the intended use dose of 2–4 mg/kg, to 20 mg/kg. The prandial state of the dog does not significantly affect the extent of its absorption.

Sarolaner was determined to have low clearance (0.12 ml/min/kg) and a moderate volume of distribution (2.81 l/kg). Half-life was comparable for the intravenous and oral routes at 12 and 11 days, respectively. Plasma protein binding was determined *in vitro* and calculated at \geq 99.9%.

A distribution study determined that ¹⁴C-sarolaner-related residues were widely distributed to the tissues. The depletion from tissues was consistent with the plasma half-life.

The primary route of elimination is biliary excretion of parent molecule, with elimination through the faeces.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

Not applicable.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 30 months.

5.3 Special precautions for storage

This veterinary medicinal product does not require any special storage conditions.

5.4 Nature and composition of immediate packaging

Aluminium foil/foil blister package.

One carton contains one blister of 3 tablets.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Zoetis Belgium

7. MARKETING AUTHORISATION NUMBER(S)

EU/2/17/220/001-006

8. DATE OF FIRST AUTHORISATION


Date of first authorisation: 31/01/2018.

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (https://medicines.health.europa.eu/veterinary).



Apalicinal problems and the second se OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

ANNEX III
LABELLING AND PACKAGE LEAFLET

AND PACE

AND PACE

Redicting

PARTICULARS TO APPEAR ON THE OUTER PACKAGE
CARTON
1 NAME OF THE VETEDINADY MEDICINAL DOODUCT
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
MiPet Easecto 5 mg chewable tablets for dogs 1.3–2.5 kg MiPet Easecto 10 mg chewable tablets for dogs >2.5–5 kg MiPet Easecto 20 mg chewable tablets for dogs >5–10 kg MiPet Easecto 40 mg chewable tablets for dogs >10–20 kg MiPet Easecto 80 mg chewable tablets for dogs >20–40 kg MiPet Easecto 120 mg chewable tablets for dogs >40–60 kg
2. STATEMENT OF ACTIVE SUBSTANCES
sarolaner 5 mg sarolaner 10 mg sarolaner 20 mg sarolaner 40 mg sarolaner 80 mg sarolaner 120 mg
3. PACKAGE SIZE
3 tablets
4. TARGET SPECIES
Dogs.
5. INDICATIONS
6. ROUTES OF ADMINISTRATION
Oral use.
7. WITHDRAWAL PERIODS
8. EXPIRY DATE
Exp. {mm/yyyy}

9. SPECIAL STORAGE PRECAUTIONS

10. THE WORDS "READ THE PACKAGE LEAFLET BEFORE USE"

Read the package leaflet before use.

11. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

12. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Zoetis Belgium

14. MARKETING AUTHORISATION NUMBERS

EU/2/17/220/001 (5 mg, 3 tablets)

EU/2/17/220/002 (10 mg, 3 tablets)

EU/2/17/220/003 (20 mg, 3 tablets)

EU/2/17/220/004 (40 mg, 3 tablets)

EU/2/17/220/005 (80 mg, 3 tablets)

EU/2/17/220/006 (120 mg, 3 tablets)

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

BLISTER

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

MiPet Easecto



2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

1.3–2.5 kg >2.5–5 kg >5–10 kg >10–20 kg >20–40 kg >40–60 kg

5 mg 10 mg 20 mg 40 mg 80 mg

120 mg

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

B. PACKAGE LEAFFEE BY ALKHORIESE VICENCE OF THE PACKAGE LEAFFEE BY ALKHORIESE VICENCE VIC

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

MiPet Easecto 5 mg chewable tablets for dogs 1.3–2.5 kg

MiPet Easecto 10 mg chewable tablets for dogs > 2.5-5 kg

MiPet Easecto 20 mg chewable tablets for dogs > 5-10 kg

MiPet Easecto 40 mg chewable tablets for dogs > 10–20 kg

MiPet Easecto 80 mg chewable tablets for dogs > 20–40 kg

MiPet Easecto 120 mg chewable tablets for dogs > 40–60 kg

2. Composition

Each tablet contains:

MiPet Easecto chewable tablets	sarolaner (mg)
for dogs 1.3–2.5 kg	5
for dogs $> 2.5-5$ kg	10
for dogs $> 5-10 \text{ kg}$	20
for dogs > 10–20 kg	40
for dogs > 20 –40 kg	80
for dogs $> 40-60 \text{ kg}$	120

Mottled brown coloured, square shaped chewable tablets with rounded edges. The number embossed on one side refers to the strength (mg) of the tablet: "5", "10", "20", "40", "80" or "120".

3. Target species

Dogs.

4. Indications for use

For the treatment of tick infestations (*Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus* and *Rhipicephalus sanguineus*). The veterinary medicinal product has immediate and persistent tick killing activity for at least 5 weeks.

For the treatment of flea infestations (*Ctenocephalides felis* and *Ctenocephalides canis*). The veterinary medicinal product has immediate and persistent flea killing activity against new infestations for at least 5 weeks. The veterinary medicinal product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD).

For the treatment of sarcoptic mange (Sarcoptes scabiei).

For the treatment of ear mite infestations (Otodectes cynotis).

For the treatment of demodicosis (*Demodex canis*).

For reduction of the risk of infection with *Babesia canis* via transmission by *Dermacentor reticulatus* for 28 days after treatment. The effect is indirect due to the veterinary medicinal product's activity against the vector.

Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

5. Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

6. Special warnings

Special warnings:

Transmission of *B. canis canis* cannot be completely excluded since *D. reticulatus* ticks have to attach to the host before being killed. As an acaricidal effect against *D. reticulatus* may take up to 48 hours, transmission of *B. canis canis* during the first 48 hours cannot be excluded.

The use of the veterinary medicinal product should be based on the local epidemiological situation including knowledge of the prevalent tick species as transmission of *B. canis* by tick species other than *D. reticulatus* is possible and should be part of an integrated control program to prevent the transmission of *Babesia canis*.

Special precautions for safe use in the target species:

Puppies less than 8 weeks of age and/or dogs less than 1.3 kg bodyweight should not be treated unless so advised by a veterinarian.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Wash hands after handling the veterinary medicinal product.

The accidental ingestion of the veterinary medicinal product may potentially result in adverse effects, such as transient excitatory neurological signs.

To prevent children from accessing the veterinary medicinal product, only one chewable tablet at a time should be removed from the blister pack and only when required. The blister pack should be returned into the carton immediately after use and the carton should be stored out of the sight and reach of children. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation or in animals intended for breeding. Laboratory studies in rats and rabbits have not produced any evidence of any teratogenic effects. The use in these animals is not recommended.

Fertility:

The safety of the veterinary medicinal product has not been established in dogs intended for breeding. The use in these animals is not recommended.

<u>Interaction with other medicinal products and other forms of interactions:</u> None known.

During clinical field trials, no interactions between this veterinary medicinal product and routinely used veterinary medicinal products were observed.

In laboratory safety studies, no interactions were observed when sarolaner was co-administered with milbernycin oxime, moxidectin and pyrantel pamoate. (In these studies efficacy was not investigated). Sarolaner is highly bound to plasma proteins and might compete with other highly bound drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) and the cumarin derivative warfarin.

Overdose:

In a margin of safety study, the veterinary medicinal product was administered orally to 8 week old Beagle puppies at doses of 0, 1, 3, and 5 times the maximum exposure dose of 4 mg/kg at 28 day intervals for 10 doses. No adverse effects were observed at the maximum exposure dose of 4 mg/kg.

In the overdose groups, transient and self-limiting neurological signs were observed in some animals: mild tremors at 3 times the maximum exposure dose and convulsions at 5 times the maximum exposure dose. All dogs recovered without treatment.

Sarolaner is well tolerated in Collies with a deficient multidrug-resistance-protein 1 (MDR1 -/-) following single oral administration at 5 times the recommended dose. No treatment-related clinical signs were observed.

7. Adverse events

Dogs:

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

gastrointestinal signs (vomiting, diarrhoea)¹, systemic disorders (lethargy, anorexia)¹, neurological signs (tremor, ataxia, convulsions)²

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}

8. Dosage for each species, routes and method of administration

For oral use.

The veterinary medicinal product should be administered at a dose of 2–4 mg/kg bodyweight in accordance with the following table:

Bodyweight (kg)	Tablet strength (mg sarolaner)	Number of tablets to be administered
1.3–2.5	5	One
> 2.5–5	10	One
> 5–10	20	One
> 10–20	40	One
> 20–40	80	One
> 40–60	120	One
> 60	Appropriate combination of tablets	

Use appropriate combination of available strengths to achieve the recommended dose of 2–4 mg/kg. To ensure a correct dosage, body weight should be determined as accurately as possible. The tablets should not be divided.

Tablets can be administered with or without food.

Treatment schedule:

For optimal control of flea and tick infestations, the veterinary medicinal product should be administered at monthly intervals and continue throughout the flea and/or tick season based on the local epidemiological situation.

¹Mild and transient.

²In most cases these signs are transient.

For the treatment of ear mite infestations (*Otodectes cynotis*) a single dose should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.

For the treatment of sarcoptic mange (caused by *Sarcoptes scabiei* var. *canis*) a single dose should be administered at monthly intervals for two consecutive months.

For the treatment of demodicosis (caused by *Demodex canis*) the administration of a single dose once monthly for three consecutive months is efficacious and leads to a marked improvement of clinical signs. Treatment should be continued until skin scrapings are negative on at least two consecutive occasions one month apart. As demodicosis is a multi-factorial disease, it is advisable to also treat any underlying disease appropriately.

9. Advice on correct administration

The tablets of this veterinary medicinal product are chewable and palatable and readily consumed by dogs when offered by the owner. If the tablet is not taken up voluntarily by the dog it can also be given with food or directly into the mouth.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions. Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the blister after Exp. The expiry date refers to the last day of that month.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

EU/2/17/220/001-006.

For each strength, the chewable tablets are available in a carton with 1 blister of 3 tablets.

15. Date on which the package leaflet was last revised

Detailed information on this veterinary medicinal product is available <u>in the</u> Union Product Database (<u>https://medicines.health.europa.eu/veterinary</u>).

16. Contact details

Marketing authorisation holder and manufacturer responsible for batch release:

Zoetis Belgium Rue Laid Burniat 1 1348 Louvain-La-Neuve Belgium

Local representatives and contact details to report suspected adverse reactions:

België/Belgique/Belgien

Zoetis Belgium Mercuriusstraat 20 BE-1930 Zaventem Tél/Tel: +32 (0) 800 99 189

Република България

Zoetis Belgium Rue Laid Burniat 1 1348 Louvain-la-Neuve Белгия

Тел: +359 888 51 30 30

Česká republika

Zoetis Česká republika, s.r.o. náměstí 14. října 642/17 CZ 150 00 Praha Tel: +420 257 101 111

Danmark

Zoetis Animal Health ApS Øster Alle 48 DK-2100 København Tlf: +45 70 20 73 05 adr.scandinavia@zoetis.com

Deutschland

Zoetis Deutschland GmbH Schellingstr. 1 DE-10785 Berlin Tel: +49 30 2020 0049 tierarzneimittelsicherheit@zoetis.com

Lietuva

Zoetis Belgium Mercuriusstraat 20 1930 Zaventem Belgija Tel: +370 610 05088

Luxembourg/Luxemburg

Zoetis Belgium Mercuriusstraat 20 1930 Zaventem Belsch

Tél/Tel: +32 (2) 746 80 11

Magyarország

Zoetis Hungary Kft. Csörsz u. 41. HU-1124 Budapest Tel.: +36 1 224 5200

Malta

Agrimed Limited Mdina Road, Zebbug ZBG 9016, MT

Tel: +356 21 465 797

Nederland

Zoetis B.V. Rivium Westlaan 74 NL-2909 LD Capelle aan den IJssel Tel: +31 (0)10 714 0900

Eesti

Zoetis Belgium Mercuriusstraat 20 1930 Zaventem Belgia

Tel: +370 610 05088

Κύπρος

Zoetis Hellas S.A. Φραγκοκκλησιάς 7, Μαρούσι 15125, Αττική Ελλάδα

Tηλ: +30 210 6791900

España

Zoetis Spain, S.L. Parque Empresarial Vía Norte Edificio nº1, c/ Quintanavides nº13 ES-28050 Madrid Tel: +34 91 4191900

France

Zoetis France 10 rue Raymond David FR-92240 Malakoff Tél: +33 (0)800 73 00 65

Hrvatska

Zoetis B.V. Podružnica Zagreb za promidžbu Petra Hektorovića 2 HR-10000 Zagreb Tel: +385 1 6441 462

Ireland

Zoetis Belgium S.A. (Irish Branch) 2nd Floor, Building 10, Cherrywood Business Park, Loughlinstown, Co. Dublin, IE – Dublin D18 T3Y1 Tel: +353 (0) 1 256 9800

Ísland

Zoetis Animal Health ApS Øster Alle 48 DK-2100 København Danmörku

Sími: +45 70 20 73 05 adr.scandinavia@zoetis.com

Norge

Zoetis Animal Health ApS Øster Alle 48 DK-2100 København Danmark Tlf: +47 23 29 86 80 adr.scandinavia@zoetis.com

Österreich

Zoetis Österreich GmbH Floridsdorfer Hauptstr. 1 AT-1210 Wien Tel: +43 (0)1 2701100 100

Polska

Zoetis Polska Sp. z o.o. ul. Postępu 17B PL - 02-676 Warszawa Tel.: +48 22 2234800

Portugal

Zoetis Portugal Lda. Lagoas Park, Edifício 10 PT-2740-271 Porto Salvo Tel: +351 21 042 72 00

România

Zoetis România S.R.L. Expo Business Park, 54A Aviator Popișteanu, Clădirea 2, Etaj 1-3, Sector 1, București, 012095 - RO Tel: +40785019479

Slovenija

Zoetis B.V.
Podružnica Zagreb za promidžbu
Petra Hektorovića 2,
10000 Zagreb,
Hrvaška
Tel: +385 1 6441 462

101. + 303 1 0441 402

Slovenská republika

Zoetis Česká republika, s.r.o. náměstí 14. října 642/17 150 00 Praha Česká republika Tel: +420 257 101 111

Italia

Zoetis Italia S.r.l. Via Andrea Doria 41M, IT-00192 Roma

Tel: +39 06 3366 8111

Ελλάδα

Zoetis Hellas S.A. Φραγκοκκλησιάς 7, Μαρούσι EL-15125 Αττική Τηλ: +30 210 6791900

Latvija

Zoetis Belgium Mercuriusstraat 20 1930 Zaventem Belģija

Tel: +370 610 05088

Suomi/Finland

Zoetis Finland Oy Bulevardi 21 / SPACES FI-00180 Helsinki/Helsingfors Suomi/Finland

Puh/Tel: +358 10 336 7000 laaketurva@zoetis.com

Sverige

Zoetis Animal Health ApS Øster Alle 48 DK-2100 Köpenhamn Danmark

Tel: +46 (0) 76 760 0677 adr.scandinavia@zoetis

United Kingdom (Northern Ireland)

Zoetis Belgium S.A. (Irish Branch) 2nd Floor, Building 10, Cherrywood Business Park, Loughlinstown, Co. Dublin, IE – Dublin D18 T3Y1 Tel: +353 (0) 1 256 9800

17. Other information

Sarolaner is an acaricide and insecticide belonging to the isoxazoline family. Sarolaner is active against adult fleas (Ctenocephalides felis and Ctenocephalides canis) as well as several tick species such as Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus, Rhipicephalus sanguineus and the mites Demodex canis, Otodectes cynotis and Sarcoptes scabiei.

For fleas, the onset of efficacy is within 8 hours of attachment during the 28 day period after product administration. For ticks (I. ricinus), the onset of efficacy is within 12 hours of attachment during the 28 day period after the veterinary medicinal product administration. Ticks on the animal prior to administration are killed within 24 hours.

The veterinary medicinal product kills newly emerged fleas on the dogs before they can lay eggs and therefore it prevents environmental flea contamination in areas to which the dog has access.